New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novo Nordisk A/S

NVO

Healthcare Drug Manufacturers General

Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.

Revenue
+3.87%
EPS
−17.1%
Free cash flow
−14.8%
Total debt
+30.7%

Quarter to September 2026, against a year earlier

38.52 0.37 −0.95%
Market cap
$128.6B
P/E
9.8×
Fwd P/E FY26e
—
Dividend yield
4.62%
F-score
5/9
ROIC
29.6%
Net debt / EBITDA
0.7×
Payout ratio
0.5×

What it owns vs. what it owes End of fiscal 2025, Dec 31, 2025

It owes $14.7B more in debt than it holds in cash and short-term investments. Debt has risen from $34.0M to $19.8B since FY16. Shareholders’ equity is 35.7% of the balance sheet. What is a balance sheet?

Dec 31, 2025 · total $82.2B

Owns

$56.1BLong-term assets
$21.0BOther short-term assets
$5.1BCash & short-term investments

Funded by

$29.4BShareholders’ equity
$33.0BOther liabilities
$19.8BDebt

Debt is 24.1% of the total; shareholders’ equity 35.7%.

It went from net cash of 22% of assets to net debt of 18% of assets since FY16.

Total assetsNet debt (debt less cash)Net debt ÷ assets (right axis)
Assets and net debt, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Total assets$14.5B$15.5B$16.9B$18.8B$22.2B$30.9B$34.2B$45.7B$67.5B$82.2B
Net debt (debt less cash)−$3.1B−$3.0B−$2.3B−$1.7B−$368M$1.2B−$73M−$808M$10.2B$14.7B
Net debt ÷ assets (right axis)−21.5%−19.0%−13.8%−8.9%−1.7%3.8%−0.2%−1.8%15.1%17.9%
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
26,109.38 23,330.06 20,276.60 15,320.27 13,618.16 10,081.94 9,362.15 9,031.35 9,126.15 8,881.23
Total non-current assets
56,085.98 44,210.21 25,386.77 18,841.72 17,328.06 12,120.11 9,467.08 7,905.24 6,421.57 5,613.07
Total Assets
82,195.36 67,540.27 45,663.37 34,161.99 30,946.22 22,202.05 18,829.24 16,936.58 15,547.72 14,494.29
Total current liabilities
32,651.08 31,541.56 24,633.91 17,125.10 15,833.00 10,765.82 8,841.55 8,281.68 7,147.81 7,048.99
Total non-current liabilities
20,165.57 15,193.25 5,556.80 5,215.27 3,857.54 1,734.84 1,354.50 728.72 833.02 718.33
Total liabilities
52,816.65 46,734.80 30,190.71 22,340.37 19,690.54 12,500.66 10,196.05 9,010.40 7,980.83 7,767.32
Common Equity (Total)
29,378.71 20,805.47 15,472.66 11,821.62 11,255.69 9,701.39 8,633.19 7,926.18 7,566.90 6,726.97
Shareholders Equity (Total)
29,378.71 20,805.47 15,472.66 11,821.62 11,255.69 9,701.39 8,633.19 7,926.18 7,566.90 6,726.97
Total Debt
19,827.04 14,904.12 3,921.27 3,651.01 4,239.22 1,586.54 672.00 78.74 257.32 34.03

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026